Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16382719 | 0.82 | KDM4E (0.38) | KDM4EAPOBEC3AAPOBEC3GMAPT | |
| SCHEMBL14981475 | 0.78 | F2RL1 (0.35) | — | |
| SCHEMBL18876106 | 0.75 | F2RL1 (0.42) | KDM4EAPOBEC3AAPOBEC3GMAPT | |
| SCHEMBL18876196 | 0.75 | HSD11B1 (0.34) | KDM4EAPOBEC3AAPOBEC3GMAPT | |
| SCHEMBL30219113 | 0.75 | KDM4E (0.33) | KDM4EAPOBEC3AAPOBEC3GMAPT | |
| SCHEMBL24981671 | 0.75 | CYP19A1 (0.34) | MAPT | |
| SCHEMBL15374083 | 0.73 | KDM4E (0.32) | KDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL29213468 | 0.71 | ALDH1A1 (0.37) | KDM4EAPOBEC3AAPOBEC3GMAPT | |
| SCHEMBL18879668 | 0.71 | IMPDH2 (0.37) | KDM4EMAPT | |
| SCHEMBL15374078 | 0.68 | KDM4E (0.34) | KDM4EAPOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190201332-A1 | Soft Chewable Pharmaceutical Products | INTERVET INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-20170100377-A1 | Solid Oral Pharmaceutical Compositions for Isoxazoline Compounds | INTERVET INC. (US) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170100377-A1 | Solid Oral Pharmaceutical Compositions for Isoxazoline Compounds | CYP3A7, SI, CYP2A7 | KDM4E 2081/4885APOBEC3A 2726/4885APOBEC3G 3026/4885 |
| US-20190201332-A1 | Soft Chewable Pharmaceutical Products | PAM, TAS2R46, TAS2R16 | KDM4E 2334/4885APOBEC3A 2291/4885APOBEC3G 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.